Brokerages expect Pacira Pharmaceuticals Inc (NASDAQ:PCRX) to announce earnings per share of $0.23 for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Pacira Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.35 and the lowest estimate coming in at $0.04. Pacira Pharmaceuticals reported earnings per share of $0.38 in the same quarter last year, which suggests a negative year-over-year growth rate of 39.5%. The business is scheduled to announce its next earnings report on Wednesday, February 27th.
On average, analysts expect that Pacira Pharmaceuticals will report full year earnings of $0.81 per share for the current year, with EPS estimates ranging from $0.60 to $0.92. For the next year, analysts expect that the business will post earnings of $1.28 per share, with EPS estimates ranging from ($0.30) to $1.87. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Pacira Pharmaceuticals.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, November 1st. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.40. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.74%. The business had revenue of $83.45 million for the quarter, compared to analysts’ expectations of $79.87 million. During the same period in the previous year, the company posted $0.11 earnings per share. The business’s revenue for the quarter was up 23.9% compared to the same quarter last year.
PCRX has been the topic of a number of recent research reports. Canaccord Genuity set a $45.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, September 4th. BMO Capital Markets boosted their target price on shares of Pacira Pharmaceuticals from $40.00 to $47.00 and gave the stock a “market perform” rating in a research report on Friday, November 2nd. Wedbush set a $90.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, November 5th. ValuEngine raised shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Finally, HC Wainwright boosted their target price on shares of Pacira Pharmaceuticals to $60.00 and gave the stock a “buy” rating in a research report on Friday, November 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have assigned a buy rating to the company. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average target price of $53.76.
In related news, VP Lauren Bullaro Riker sold 1,000 shares of the company’s stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $54.35, for a total value of $54,350.00. Following the sale, the vice president now directly owns 11,474 shares of the company’s stock, valued at $623,611.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gary W. Pace bought 4,000 shares of the stock in a transaction on Wednesday, November 7th. The shares were acquired at an average price of $51.29 per share, with a total value of $205,160.00. Following the purchase, the director now owns 28,319 shares of the company’s stock, valued at $1,452,481.51. The disclosure for this purchase can be found here. Insiders sold 151,221 shares of company stock worth $7,403,146 over the last ninety days. 5.90% of the stock is currently owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE increased its stake in Pacira Pharmaceuticals by 40.7% during the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock valued at $194,000 after purchasing an additional 1,746 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Pacira Pharmaceuticals by 1,925.8% during the second quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock valued at $214,000 after purchasing an additional 6,336 shares during the last quarter. Xact Kapitalforvaltning AB bought a new stake in Pacira Pharmaceuticals during the second quarter valued at $219,000. Bouchey Financial Group Ltd bought a new stake in Pacira Pharmaceuticals during the third quarter valued at $221,000. Finally, Boston Private Wealth LLC bought a new stake in Pacira Pharmaceuticals during the third quarter valued at $246,000. Hedge funds and other institutional investors own 97.84% of the company’s stock.
Shares of NASDAQ PCRX traded down $1.91 during trading on Friday, reaching $46.23. 440,252 shares of the stock were exchanged, compared to its average volume of 397,112. Pacira Pharmaceuticals has a twelve month low of $26.95 and a twelve month high of $55.00. The company has a current ratio of 8.66, a quick ratio of 7.83 and a debt-to-equity ratio of 0.95. The stock has a market cap of $1.98 billion, a P/E ratio of -79.71 and a beta of 1.65.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.
Recommended Story: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.